Local MP, Steve Brine, recently visited a Chandler’s Ford-based business at the forefront of pandemic preparedness and fighting infectious diseases.
Novacyt, a clinical diagnostic company, has a long-established heritage in innovation, research and development, manufacturing and global supply of high-quality diagnostic products. Novacyt is proud to have been one of the first companies to successfully respond to outbreaks of swine flu, zika, ebola, the COVID-19 pandemic and more recently, monkeypox.
The company played a critical role in protecting lives during the pandemic. With its laboratories in Chandler’s Ford, the company utilised their R&D capabilities and manufacturing scale up to rapidly develop and deploy PCR tests and instruments, becoming the first manufacturer of COVID-19 PCR tests to receive CE certification in Europe.
Reflecting on the visit, Mr Brine said; “It was a pleasure to visit Novacyt to hear about their proud history in fighting infectious diseases and more recently their contribution to the COVID-19 pandemic.
“This fantastic local business is at the forefront of humanity’s fight against infectious diseases. Novacyt’s ability to respond rapidly to the pandemic is proof of their ability to contribute to global health, and I am sure they will continue to play a key part in our first line of defence in the future.
“I am confident in Novacyt’s ability to continue to adapt to emerging threats and I am excited to see how the business continues to develop and grow in Chandler’s Ford. The government must create the environment for a robust diagnostics industry by supporting homegrown innovation.”
Commenting on the company’s future, David Allmond, Group CEO of Novacyt said; “Novacyt remains well positioned for future growth and value creation as we move past the pandemic and continue our journey to become a leading global clinical diagnostics company focused on decentralised diagnostic testing and unmet medical needs in infectious diseases.
“We are pleased with the progress we have made in the development of the post-COVID-19 product portfolio, and we will continue to innovate and invest in the UK.
“We are proud of our workforce and in the development of local talent in the Chandler’s Ford area. Our highly talented team will continue to build upon our proven track record in rapidly responding to disease outbreaks to add value to global health.”
Pictured; Steve Brine MP with Novacyt Chief Executive, David Allmond.
Pictured; From left to right, Nick East, Paul Oladimeji, Steve Brine MP, David Allmond and Peter Hall.
